{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:02:50Z","timestamp":1790870570541,"version":"4.1.0"},"reference-count":13,"publisher":"Ordem dos Medicos","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Med Port"],"abstract":"<jats:p>Introduction: Dostarlimab has been available in Portugal for advanced or recurrent endometrial cancer post\u2013platinum therapy via an early access program (EAP) since November 2021, with reimbursement from October 2024; its use with carboplatin and paclitaxel was authorized under an early access program in June 2024. The aim of this study was to assess the efficacy and safety of dostarlimab in a Portuguese cohort of endometrial cancer patients.Methods: This is a national multicenter retrospective cohort study involving patients treated with dostarlimab between January 2022 and January 2025 in 13 hospitals. Safety endpoints were rate of grade \u2265 3 adverse events (AE) and the treatment discontinuation rate. Efficacy endpoints were disease control rate (DCR), overall response rate (ORR) and six-month progression-free survival (PFS), in the monotherapy and the chemotherapy-combination groups.Results: The study assessed 43 patients, with a median follow-up time of six (3 - 14) months. In the chemotherapy-combination group (n = 13), mean age was 62.77 \u00b1 8.4 years-old; the most common histological subtype was endometrioid (69.2%), but 23.1% were carcinosarcoma. Both ORR and DCR were 84.6%. In the monotherapy group (n = 30), the median number of previous treatment lines was 1 (1 - 6). Mean age was 67.43 \u00b1 9.44 years. Endometrioid was the most prevalent histology (83.3%), followed by serous (6.6%). Overall response rate was 53.3% and DCR 63.3%. The six-month PFS was 68.4% (95% CI: 51% - 86%) in the monotherapy group and 83.1% (95% CI: 62% - 100%) in the combination group. Regarding safety, only 13.9% of patients reported grade \u2265 3 AE and the discontinuation rate was 9.3%.Conclusion: The results show compatible findings with current data regarding efficacy and manageable toxicity and may support the role of an early access program in improving treatment availability for patients with limited therapeutic options.<\/jats:p>","DOI":"10.20344\/amp.24371","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:34:02Z","timestamp":1790843642000},"page":"608-616","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Use of Dostarlimab in Endometrial Cancer: A Portuguese Multicenter Study"],"prefix":"10.20344","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-7885","authenticated-orcid":false,"given":"Margarida","family":"Quinto Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3356-1969","authenticated-orcid":false,"given":"Pedro","family":"Antunes Meireles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-0834","authenticated-orcid":false,"given":"Ana Rita","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9891-8009","authenticated-orcid":false,"given":"Maria Teresa","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Gomes Zanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Soares de Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9631-9568","authenticated-orcid":false,"given":"Paulo","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9895-4053","authenticated-orcid":false,"given":"Beatriz","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7621","authenticated-orcid":false,"given":"Pedro","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-6536","authenticated-orcid":false,"given":"Filipa","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RIta","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8464","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"13628","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.","DOI":"10.3322\/caac.21660"},{"key":"13629","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, er al. Global Cancer Observatory: cancer today. Lyon: International Agency for Research on Cancer; 2024."},{"key":"13630","doi-asserted-by":"crossref","unstructured":"Stelloo E, Nout RA, Osse EM, J\u00fcrgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer\u2014combined analysis of the PORTEC cohorts. Clini Cancer Res. 2016;22:4215-24.","DOI":"10.1158\/1078-0432.CCR-15-2878"},{"key":"13631","doi-asserted-by":"crossref","unstructured":"Levine DA, The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013:497;67\u201373.","DOI":"10.1038\/nature12113"},{"key":"13632","doi-asserted-by":"crossref","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J M. 2015;372:2509-20.","DOI":"10.1200\/jco.2015.33.15_suppl.lba100"},{"key":"13633","doi-asserted-by":"crossref","unstructured":"Ambrosini M, Manca P, Nasca V, Sciortino C, Ghelardi F, Seligmann JF, et al. Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat Rev Clin Oncol. 2025;22:385-407.","DOI":"10.1038\/s41571-025-01015-z"},{"key":"13634","doi-asserted-by":"crossref","unstructured":"Tuninetti V, Farolfi A, Rognone C, Montanari D, De Giorgi U, Valabrega G. Treatment strategies for advanced endometrial cancer according to molecular classification. Int J M Sci. 2024;25:11448.","DOI":"10.3390\/ijms252111448"},{"key":"13635","doi-asserted-by":"crossref","unstructured":"Eskander RN. Implications of the platinum-free interval in endometrial cancer: A legacy worth leaving behind? Gynecol Oncol. 2025;194:A3-4.","DOI":"10.1016\/j.ygyno.2025.03.026"},{"key":"13636","doi-asserted-by":"crossref","unstructured":"Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, et al. Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin Cancer Res. 2023 ;29:4564-74.","DOI":"10.1158\/1078-0432.CCR-22-3915"},{"key":"13637","doi-asserted-by":"crossref","unstructured":"Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov\u00e1k Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145-58.","DOI":"10.1056\/NEJMoa2216334"},{"key":"13638","doi-asserted-by":"crossref","unstructured":"Powell MA, Cibula D, O\u2019Malley DM, Boere I, Shahin MS, Savarese A, et al Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY). Gynecol Oncol. 2025;192:40-9.","DOI":"10.1016\/j.ygyno.2024.10.022"},{"key":"13639","doi-asserted-by":"crossref","unstructured":"Kim MK, Kim K, Lee YY, Nam EJ, Lim MC, Kim KH, et al. 397P Real-world outcome of dostarlimab in dMMR\/MSI-H advanced\/recurrent endometrial cancer: Updated results from Korean expanded access program. Ann Oncol. 2024;35:S1552.","DOI":"10.1016\/j.annonc.2024.10.418"},{"key":"13640","doi-asserted-by":"crossref","unstructured":"Rodrigues M, Eberst L, Follana P, Gauthier L, Jacquemin V, Tessier C, et al. Real-world dostarlimab use in advanced\/recurrent endometrial cancer in France. Bull Cancer. 2023;110:1041-50.","DOI":"10.1016\/j.bulcan.2023.06.009"}],"container-title":["Acta M\u00e9dica Portuguesa"],"original-title":[],"link":[{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/24371\/16042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/24371\/16042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:40:06Z","timestamp":1790869206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/view\/24371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.20344\/amp.24371","relation":{},"ISSN":["1646-0758","0870-399X"],"issn-type":[{"value":"1646-0758","type":"electronic"},{"value":"0870-399X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}